Travere Therapeutics, Inc. TVTX Cash, Cash Equivalents, and Marketable Securities
Cash, Cash Equivalents, and Marketable Securities at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecurities.
The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Travere Therapeutics, Inc.'s cash, cash equivalents, and marketable securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Travere Therapeutics, Inc.'s cash, cash equivalents, and marketable securities?
- Travere Therapeutics, Inc. (TVTX) reported cash, cash equivalents, and marketable securities of $186.31M in Q1 2026.
- How has Travere Therapeutics, Inc.'s cash, cash equivalents, and marketable securities changed year-over-year?
- Travere Therapeutics, Inc.'s cash, cash equivalents, and marketable securities decreased by 28.4% year-over-year, from $260.35M to $186.31M.
- What is the long-term trend for Travere Therapeutics, Inc.'s cash, cash equivalents, and marketable securities?
- Over 5 years (2020 to 2025), Travere Therapeutics, Inc.'s cash, cash equivalents, and marketable securities has grown at a -3.7% compound annual growth rate (CAGR), from $276.82M to $229.76M.
- What does cash, cash equivalents, and marketable securities mean?
- This represents the most liquid assets held by the company, including cash on hand, bank deposits, and short-term investments that can be readily converted into cash. It serves as the primary buffer for operational liquidity and potential capital allocation activities. Investors monitor this to assess the company's ability to meet short-term obligations and fund growth initiatives.